Xu Xiaoyun, Huang Jinsha, Li Jie, Liu Ling, Han Chao, Shen Yan, Zhang Guoxin, Jiang Haiyang, Lin Zhicheng, Xiong Nian, Wang Tao
Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Department of Psychiatry, Harvard Medical School, Division of Alcohol and Drug Abuse, Mailman Neuroscience Research Center, McLean Hospital, Belmont, MA, USA.
Cell Prolif. 2016 Feb;49(1):14-26. doi: 10.1111/cpr.12229. Epub 2016 Jan 8.
Many neurodegenerative disorders, such as Parkinson's disease (PD), are characterized by progressive neuronal loss in different regions of the central nervous system, contributing to brain dysfunction in the relevant patients. Stem cell therapy holds great promise for PD patients, including with foetal ventral mesencephalic cells, human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs). Moreover, stem cells can be used to model neurodegenerative diseases in order to screen potential medication and explore their mechanisms of disease. However, related ethical issues, immunological rejection and lack of canonical grafting protocols limit common clinical use of stem cells. iPSCs, derived from reprogrammed somatic cells, provide new hope for cell replacement therapy. In this review, recent development in stem cell treatment for PD, using hiPSCs, as well as the potential value of hiPSCs in modelling for PD, have been summarized for application of iPSCs technology to clinical translation for PD treatment.
许多神经退行性疾病，如帕金森病（PD），其特征是中枢神经系统不同区域的神经元进行性丧失，导致相关患者出现脑功能障碍。干细胞疗法对PD患者具有巨大潜力，包括使用胎儿腹侧中脑细胞、人类胚胎干细胞（hESC）和人类诱导多能干细胞（hiPSC）。此外，干细胞可用于模拟神经退行性疾病，以筛选潜在药物并探索其发病机制。然而，相关的伦理问题、免疫排斥以及缺乏规范的移植方案限制了干细胞在临床上的普遍应用。由重编程体细胞衍生而来的hiPSC为细胞替代疗法带来了新希望。在本综述中，总结了使用hiPSC进行PD干细胞治疗的最新进展，以及hiPSC在PD建模中的潜在价值，以便将iPSC技术应用于PD治疗的临床转化。
